I-125 implant and supervoltage irradiation for treatment of T0-2 or T3 carcinoma of the prostate. The impact of invasion beyond the prostatic capsule and minimal nodal involvement.
Sixty-three consecutive patients with cancer of the prostate treated by pelvic lymphadenectomy, I-125 implantation +/- Co60 therapy were studied regarding the impact of extension of cancer beyond the capsule and minimal nodal involvement. Extension of cancer beyond the prostatic capsule, Stage T3, constituted 34%, while Stages T0-2 comprised 66% of the cases. The features of T3 compared with T2 or less were: higher incidence of younger age (50s), 29% vs. 19%; less well-differentiated cancer, 29% vs. 64%; higher incidence of pelvic node involvement, 52% vs. 18%; and higher incidence of recurrence, 24% vs. 4.7%. The involvement of only one or two pelvic nodes by microscopic cancer did not adversely affect the prognosis in T2 group over a relatively short period of follow-up. No local recurrence occurred in T2. In the T3 group, two of 21 (9.5%) developed local recurrence.
D000368:Aged; D001918:Brachytherapy; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011882:Radiotherapy, High-Energy
D003037:Cobalt Radioisotopes; D007457:Iodine Radioisotopes